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Abstract  
AIM: The purpose of this study is to see the effect of Dexketoprofen on TNF-α, IL-1, and IL-6 serum 
levels in Chronic Tension-Type Headache (CTTH) patients and its correlation with pain severity.  
METHOD: The study subjects were recruited consecutively from the study population. Venous 
blood was taken at baseline to measure serum levels of TNF-α, IL-1, and IL-6 and after ten 
consecutive days of Dexketoprofen 25 mg once daily.
 
RESULTS: Twenty three subjects participated in this study, 3 male (13.0%) and 20 female (87%). 
A significant difference between NRS score at baseline and after treatment (4.86 ± 1.82 vs. 1.96 ± 
1.40, p = 0.001) was found. No significant difference found between baseline and after treatment 
TNF-α (1.48 ± 0.65 pg/dl vs. 1.48 ± 0.63 pg/dl, p = 0.963), IL-1 (0.16 ± 0.80 pg/dl vs. 0.26 ± 0.31 
pg/dl, p = 0.168) nor IL-6 serum levels (1.06 ± 0.83 pg/dl vs. 1.04 ± 0.81 pg/dl, p = 0.915). A weak 
negative (R = -0.266) non significant correlation (p = 0.219) was found between NRS score and 
TNF-α. A positive weak negative (R = 0.221) non significant correlation (p = 0.311) between NRS 
score and IL-1. NRS score and IL-6 had a negative very weak (R = -0.019) non significant negative 
correlation (p = 0.931). 
CONCLUSIONS: Dexketoprofen decreased pain intensity significantly (p = 0.001), but had no 
effect on TNF-α IL-1 nor IL-6 serum levels. NRS score had a weak and non significant negative 
correlation with TNF-α, a weak and non significant positive correlation with IL-1, and a very weak 
and non significant negative correlation with IL-6 serum levels.
 
 
 
 
Introduction 
 
 A tension-type headache (TTH) is the most 
common form of a primary headache. Chronic 
tension-type headache (CTTH) differs from the 
episodic forms not only in frequency but also on 
pathophysiology, lack of effect of most treatment 
strategies, more medication overuse, more disability, 
and higher personal and socioeconomic costs [1]. 
Globally, the percentages of the adult population with 
an active headache disorder are 46a % headache in 
general, 11a % migraine, 42% TTH and 3% chronic 
daily headache [2]. 
 
In the past, several studies have measured 
the levels of cytokines in the blood of headache 
patients, mostly migraine. Bo et al., studied the level 
of cytokines in cerebrospinal fluid (CSF) in headache 
patients and found elevated levels of IL-1, TGF-b1 
(transforming growth factor-b1), and MCP-1 
(monocyte chemoattractant protein-1) in episodic 
tension-type headache (ETTH) and migraine 
compared to controls, and there were significant 
differences in MCP-1 between carcinogenic headache 
and migraine without aura [3]. Kocer found an 
increasing level of IL-6 in patients with ETTH and 
CTTH compared to controls. Therefore, they believe 
that IL-6 is involved in the induction of pain or 
inflammatory mechanisms in TTH [4].
 
One study by 
Backonja also found elevated receptor levels of TNF 
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in CSF and blood, elevated levels of IL-1β in CSF that 
was associated with pain intensity, whereas IL-10 was 
inversely correlated with pain symptoms [5]. Serum 
levels of IL-1β were significantly elevated in CTTH 
patients compare to healthy controls, while IL-18 
levels were significantly elevated in men with CTTH, 
in a study by Vedova et.al [6].  
 Dexketoprofen Trometamol, a COX-inhibitor 
is administered orally with max 0.25-0.75 hours. 
Dexketoprofen is superior to placebo in relieving 
moderate to severe pain. Dose-response relationship 
between 12.5 mg and 25 mg can be seen as a time-
effect curve, where the superiority of Dexketoprofen 
25 mg is more likely due to the duration of action 
expansion more than increasing dosage. The 
medicine is also well tolerated [7].  
 Prior studies have found a positive 
relationship between the numbers of cytokines with 
some types of a headache. Unfortunately, most 
measurements of cytokine levels were performed in 
the CSF make it relatively difficult for routine 
examination in daily practice. The purpose of this 
study is to measure the serum levels of TNF-α, IL-1, 
IL-6 in CTTH patients before and after given 
Dexketoprofen and its correlation with pain severity.  
 
 
Material and Methods 
  
This research was done at the Adam Malik 
Hospital and Bukit Barisan Army Hospital Medan, 
Indonesia from January 2013 - June 2014 and 
approved by the Ethics Committee for Health 
Research School of Medicine in University of 
Sumatera Utara. The subjects were recruited 
consecutively from the study population. Diagnosis of 
CTTH was made based on the diagnostic criteria as 
stated in the ICH-X. NRS score was taken from all 
subjects at baseline as well as blood for TNF-α, IL-1 
and IL-6 serum level measurement. Each subject was 
given Dexketoprofen 25 mg once daily for ten 
consecutive days. The day after the last dosage, all 
subjects were asked to score their pain severity at that 
time by using NRS. The second blood samples were 
taken for the second TNF-α, IL-1 and IL-6 serum level 
measurement. T-paired test with the level of 
significance p < 0.5 was performed to analyse 
differences between NRS score, TNF-α, IL-1 and IL-6 
serum before and after Dexketoprofen administration. 
 
Results 
 Data from 23 subjects who followed the whole 
procedure were analysed further. Twenty-three CTTH 
patients participated in this study, three subjects were 
men (13.0%), and 20 subjects were women (87%). 
There was a significant difference (p = 0.001) between 
baseline NRS score (4.86 ± 1.82) with NRS score 
after Dexketoprofen administration (1.96 ± 1.40). No 
significant difference (p = 0.963) was found between 
baseline TNF-α (1.48 ± 0.65 pg/dl) with TNF-α level 
after treatment (1.48 ± 0.63 pg/dl). There is also no 
significant difference was found between baseline and 
after 10-day Dexketoprofen administration for IL-1 
serum (0.16 ± 0.80 pg/dl vs 0.26 ± 0.31 pg/dl, p = 
0.168) and IL-6 serum (1.06 ± 0.83 pg/dl vs 1.04 ± 
0.81 pg/dl, p = 0.687) (Table 1).  
Table 1: NRS score, TNF-α, IL-1 and IL-6 serum level before 
and after Dexketoprofen administration 
Variable 
Dexketoprofen 
p * 
Before (n ; x ± SD) After (n ; x ± SD) 
NRS 23 ; 4,86 ± 1,82 23 ; 1,96 ± 1,40 0,001 ** 
TNF-α 23 ; 1,48 ± 0,65 23 ; 1,48 ± 0,63  0,963 
IL-1 23 ; 0,16 ± 0,80 23 ; 0,26 ± 0,31 0,168 
IL-6 23 ; 1,06 ± 0,83 23 ; 1,04 ± 0,81 0,915 
 
After Dexketoprofen administration, the NRS 
score showed a weak negative and non-significant 
correlation with the serum level of TNF- α (R = -0.266; 
p = 0.219). NRS score has a weak positive non 
significant correlation with IL-1 serum level (R = 0.221; 
p = 0.311), and a very weak negative and non 
significant correlation with IL-6 (R = -0.019; p = 0.931) 
(Table 2). 
Table 2: Correlation between NRS score and TNF-α, kadar IL-1 
and kadar IL-6 serum level after Dexketoprofen administration 
NRS after Dexketoprofen 
administration 
 TNF-α IL-1 IL-6 
R -0,266 0,221 - 0,019 
P 0,219 0,311 0,932 
N 23 23 23 
 
 
Discussion 
  
At baseline, the mean of the NRS score was 
4.86 ± 1.82 and became 1.96 ± 1.40 after 
Dexketoprofen administration. There was a significant 
decrement of the NRS score with p = 0.001. This fact 
suggests that Dexketoprofen is effective to lower the 
pain intensity in CTTH patients. Dexketoprofen is an 
(S)-enantiomer of ketoprofen. Ketoprofen racemic is 
an effective analgetic and anti-inflammatory agent and 
consider as a potent inhibitor of prostaglandin 
synthesis in vitro [7]. Dexketoprofen is a nonsteroidal 
anti-inflammatory drug which inhibits the cyclo-
oxygenase one dan two enzymes (COX-1 dan COX-
2) centrally and peripherally [8]. The facts that 
Dexketoprofen significantly decreased the pain 
intensity, but has no effect on the serum levels of 
TNF-α, IL-1 and IL-6 proved that these cytokines play 
non-significant roles in the pathophysiology of pain in 
CTTH patients. This study also found inconsistent 
correlations between NRS and TNF-α, IL-1 and IL-6 
serum levels, furthermore, support the possibility of 
other mechanisms that may be responsible for pain 
generating process in CTTH patients. 
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Before Dexketoprofen administration, the 
mean of TNF-α serum level was 1.48 ± 0.65 pg/dl and 
became 1.48 ± 0.63 pg/dl after administration. There 
was a non-significant change of the mean of TNF-α 
serum level (p = 0.963). This data suggest that TNF-α 
serum level had no correlation with decreased pain 
intensity after Dexketoprofen administration in CTTH 
patients, differs from the previous study. A study by 
Bo et.al in 2008, showed significant differences 
between the CSF level of IL-1ra, TGF-β1 and MCP-1 
in TTH and migraine patients when compared to the 
control group [3]. The non-significant result of TNF-α 
in this study is by several previous studies. Tanure 
et.al. found no significant difference in the level of 
TNF-α, sTNFR1 and sTNFR2 during a migraine attack 
and headache-free period [9]. In headache patients, 
the cytokines were only increased slightly if compared 
to other severe neurological diseases. This increment 
was considered as a slight response of cytokine 
toward a headache [10]. A study by Rozen et al. found 
an increment of TNF-α in CSF of New Daily Persistent 
Headache (NDPH) and migraine patients. But the 
increment was not found in serum [11]. TNF-α is the 
primary pro-inflammatory cytokine for brain infection 
diseases. In normal condition, this cytokine is 
produced in a very small quantity. In the state of 
infection, where there is a strong stimulation by 
microorganisms, the production will greatly increase 
so that it can be detected in blood with a quite 
significant level [12]. The non-significant finding in this 
study maybe due to the measurement of TNF-α was 
performed in the serum where more confounding 
variables found compare to CSF. The very low serum 
level of TNF-α found in this study was probably 
indicated that in CTTH patients, the only very small 
amount of TNF-α produced, in contrast with during 
brain infection. 
There was a contradictory of significance in 
the result between NRS score and TNF-α serum level, 
before and after Dexketoprofen administration. With p 
= 0.001, Dexketoprofen effectively reduced pain 
intensity. On the other side, p = 0.963 after 
Dexketoprofen administration, suggest that TNF-α 
level was not significantly decreased as a result of 
Dexketoprofen administration. This fact suggests that 
pain intensity decrement due to Dexketoprofen 
administration was not through TNF-α decrement 
mechanism. Regarding pain, there were still many 
biological mechanisms of Dexketoprofen, which were 
still not fully understood [13]. Many in vitro studies 
regarding the effect of TNF-α on CNS has been 
performed, with still ambiguous conclusions [14]. 
Before Dexketoprofen administration, the mean level 
of IL-1 was 0.16 ± 0.80 and it became 0.26 ± 0.31 
after administration (p = 0.168). This fact showed that 
IL-1 serum level did not significantly decrease pain 
intensity as a result of Dexketoprofen administration in 
chronic TTH patients. Together, IL-1 and IL-6 causes 
trigeminal nociceptor sensitization and play an 
important role in migraine pathogenesis by reducing 
sensitivity threshold toward other inflammatory 
stimulus [15]. As strong mediators for fever, pain, and 
inflammation, IL-1 and TNF-α function via 
hypothalamic induction [12, 16]. Research by Bo et al 
found an increment of cytokine IL-1, TGF-β1 and 
MCP-1 level in ETTH and migraine patients’ CSF [3]. 
The non-significant result on the IL-1 level in this 
research was by previous studies. In normal condition, 
the IL-1 production is very small. In infection condition, 
where there is a strong stimulation by micro 
organisms, the production will greatly elevate so that it 
can be detected in blood with a quite significant level 
[12]. The small quantity of IL-1 in this study was 
caused by an inflammatory process such as in TTH 
and not an infectious process of the brain. 
There was contradictory of significance in the 
result between NRS score and IL-1 serum level, 
before and after Dexketoprofen administration. With p 
= 0.001, it means that Dexketoprofen effectively 
reduced pain intensity. On the other side, p = 0.168 
after Dexketoprofen administration, suggests that IL-1 
level was not significantly different as a result of 
Dexketoprofen administration. This fact suggests that 
pain intensity decrement due to Dexketoprofen 
administration was not through IL-1 decrement 
mechanism. Regarding pain, there were still many 
biological mechanisms of Dexketoprofen, which were 
still not fully understood [13]. The correlation between 
IL-1 and Dexketoprofen in reducing pain intensity is 
still unclear. 
Before drug administration, the level of IL-6 = 
1.06 ± 0.83, and after administration, it became 1.04 ± 
0.81 with no significant difference between them (p = 
0.915). This fact showed that IL-1 serum level did not 
significantly decrease pain intensity as a result of 
Dexketoprofen administration in chronic TTH. 
Interleukin-6 function as a pro and anti-inflammation, 
secreted by T-cell and acts as an initial response 
toward infection and trauma. This substance can 
penetrate the blood-brain barrier and initiates PGE2in 
hypothalamus, thus elevating body temperature. 
Whenever infection occurs, production of IL-6 will 
increase [17]. Systemic effect of IL-1 will cause 
induction of fever, acute phase protein plasma 
synthesis by the liver, and directly stimulate the 
production of IL-6, and production of neutrophil and 
platelet in bone marrow [15]. In migraineurs, it has 
been suggested that IL-6 level increase during the 
headache phase. A study by Yan et al. showed that 
IL-6 strengthen excitability of dura mater afferent fibre 
so that sensitization which contributed toward a 
pathophysiology migraine headache occurred [18]. 
From statistical analysis, there was a non-
significant difference of IL-6 level, with p = 0.915, after 
Dexketoprofen administration. The non-significant 
result of IL-6 in this study was supported by previous 
study results. The same as TNF-α and IL-1, IL-6 is 
very responsive toward infection [17]. Regarding pain 
in an animal experiment, IL-6 can stimulate trigeminal 
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ganglion cell to synthesise COX-2 and PGE2, which 
will release CGRP that causes pain [19]. Bo et al. did 
not reveal any significant difference in CSF level of 
several pro-inflammatory cytokines in TTH, migraine, 
and carcinogenic headache [3]. But, IL-6 pain-related 
detection in those studies was obtained through LCS, 
not serum. 
There was contradictory of the result between 
NRS score and IL-6 serum level, before and after 
Dexketoprofen administration. With p = 0.001, it 
means that Dexketoprofen effectively reduced pain 
intensity. On the other side, p = 0.915 after 
Dexketoprofen administration, suggest that IL-6 level 
was not significantly different as a result of 
Dexketoprofen administration. Regarding pain, there 
were still many biological mechanisms of 
Dexketoprofen, which were still not fully understood 
[13]. This fact suggests that pain intensity decrement 
due to Dexketoprofen administration was not through 
IL-6 decrement mechanism.
 
 In these subjects, there was statistically 
significant decrement of pain intensity based on the 
mean of NRS score (p = 0.001), from 4.86 ± 1.82 
(before) to 1.96 ± 1.40 (after). There was a non 
significant (p = 0.963) change of the mean of TNF-α 
serum level, from 1.48 ± 0.65 pg/ml (before 
administration) to 1.48 ± 0.63 pg/ml (after 
administration). As for IL-1 and IL-6 serum level, there 
was also non-significant difference between before 
and after administration (p = 0.168 and p = 0.915 
respectively). After Dexketoprofen administration, 
TNF-α serum level had a weak negative correlation (R 
=         -0.266) and non-significant (p = 0.219) with 
pain intensity. There was a weak, non-significant 
positive correlation (R = 0.221; p = 0.311) between 
pain intensity and IL-1 serum level and a very weak, 
non-significant correlation (R = -0.019; p = 0.932) 
between pain intensity and IL-6 serum level. 
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